BROSSARD, Quebec, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces its exclusive strategic partnership agreement with Labtician Ophthalmics (“Labtician”), a Toronto-based company with customers across Canada who will introduce and commercialize DIAGNOS AI platform to monitor ocular health and improve patient care in diabetic patients. An initial agreement with Labtician was announced on June 3rd, 2020.
In an effort to increase its footprint and accelerate its growth, DIAGNOS has decided to work with organizations that are active in similar markets. The formalization of this strategic partnership with Labtician will have the net effect of allowing access to new customers across Canada. DIAGNOS’ CARA solution allows close monitoring of the effects of medications used in retinal microcirculation to help professionals in their day-to-day screening of their patients.
“We are pleased to be working with DIAGNOS in addressing growing needs in the monitoring of diabetic and hypertensive patients. For over 60 years, we’ve been world leaders in innovative eye care products, solutions, and resources for eyecare professionals and their patients. Through our extensive network, we commercialize our high-quality eyecare products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels,” explains Labtician President, Polydor Strouthos.
“I am pleased to be working with the team at Labtician. Labtician brings a high-level of expertise in the Canadian healthcare marketplace. Our growth strategy is to create partnerships in select countries thereby leveraging local relationships to accelerate the adoption of DIAGNOS’ CARA AI Platform. Labtician is the ideal partner due to their long history of working closely with Canadian Optometric and Ophthalmology professionals dedicated to treating the effects of diabetes on the eyes and preventing vision loss,” explains DIAGNOS CEO, André Larente.
Labtician worked with Prism Eye Institute, a CAN Health Network partner, to gain insights in how to best utilize this revolutionary screening technology in the Canadian market. With these insights, Labtician was able to find ways to bring this technology to Canadians using existing care models. The CAN Health Network is focused on building an integrated market and supporting Canadian companies scale.
“More retina screening means earlier intervention, better care, and a massive savings to the system,” said Dr. Ike Ahmed, world renowned Ophthalmologist and Medical Director at Prism Eye Institute, who has led the efforts as part of his commitment to the CAN Health Network. “We are strong supporters of the CAN Health Network and helping world-class Canadian health tech companies succeed. By supporting Canadian companies, our patient’s community and economy all benefit.”
With 60 years of history in Canada, Labtician has evolved from a manufacturer of quality ophthalmic products for the global market to a specialized commercialization partner for the Canadian ophthalmic market. In their capacity as a commercialization partner, they offer the “complete Canadian solution.” Labtician is actively involved in the entire commercialization process from pre-launch, to launch and post-launch. This involves regulatory, market access, importation and distribution as well as sales and marketing activities. Internationally, they offer commercialization expertise through global partners.
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available atwww.diagnos.com and www.sedar.com
This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
Tel: 450-678-8882 ext. 224
© 2022 Canjex Publishing Ltd. All rights reserved.